Patents Assigned to Gilead Pharmasset LLC
  • Patent number: 10344019
    Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: July 9, 2019
    Assignee: Gilead Pharmasset LLC
    Inventors: Elizabeth M. Bacon, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, Evan S. Krygowski, John O. Link, James G. Taylor, Chinh Tran, Teresa Alejandra Trejo Martin, Zheng-Yu Yang, Sheila M. Zipfel
  • Patent number: 10335409
    Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: July 2, 2019
    Assignee: Gilead Pharmasset LLC
    Inventors: Kyla Bjornson, Eda Canales, Jeromy J. Cottell, Kapil K. Karki, Ashley A. Katana, Darryl Kato, Tetsuya Kobayashi, John O. Link, Ruben Martinez, Barton W. Phillips, Hyung-jung Pyun, Michael Sangi, Adam J. Schrier, Dustin Siegel, James G. Taylor, Chinh V. Tran, Teresa A. Trejo Martin, Randall W. Vivian, Zheng-Yu Yang, Jeff Zablocki, Sheila Zipfel
  • Patent number: 10287311
    Abstract: The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2?R)-2?-deoxy-2?-fluoro-2?-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: May 14, 2019
    Assignee: GILEAD PHARMASSET LLC
    Inventor: Jeremy Clark
  • Patent number: 10183037
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: January 22, 2019
    Assignee: Gilead Pharmasset LLC
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
  • Patent number: 10100076
    Abstract: The disclosed invention is a composition for and a method of seating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: October 16, 2018
    Assignee: Gilead Pharmasset LLC
    Inventors: Lieven Stuyver, Kyoichi Watanabe
  • Patent number: 10086011
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: October 2, 2018
    Assignee: Gilead Pharmasset LLC
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • Patent number: 10039779
    Abstract: Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: August 7, 2018
    Assignee: Gilead Pharmasset LLC
    Inventors: Ben Chal, Erik Mogalian, Reza Oliyai, Rowchanak Pakdaman, Dimitrios Stefanidis, Vahid Zia
  • Patent number: 9981955
    Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: May 29, 2018
    Assignee: Gilead Pharmasset LLC
    Inventors: Elizabeth M. Bacon, Eda Canales, Aesop Cho, Jeromy J. Cottell, Manoj C. Desai, Michael Graupe, Hongyan Guo, Randall L. Halcomb, Darryl Kato, Choung U. Kim, Thorsten A. Kirschberg, Evan S. Krygowski, Scott E. Lazerwith, John O. Link, Hongtao Liu, Qi Liu, Richard L. Mackman, Michael L. Mitchell, Jay P. Parrish, Hyung-Jung Pyun, Joseph H. Saugier, Scott D. Schroeder, Jianyu Sun, James G. Taylor, James D. Trenkle, Winston C. Tse, Randall W. Vivian, William J. Watkins, Lianhong Xu
  • Patent number: 9890134
    Abstract: The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: February 13, 2018
    Assignee: Gilead Pharmasset LLC
    Inventors: Kevin M. Allan, Shinji Fujimori, Lars V. Heumann, Grace May Huynh, Katie Ann Keaton, Chrisopher M. Levins, Ganapati Reddy Pamulapati, Benjamin James Roberts, Keshab Sarma, Martin Gerald Teresk, Xiang Wang, Scott Alan Wolckenhauer
  • Patent number: 9884873
    Abstract: Crystalline solid forms of methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4?,3?:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using these crystalline forms.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: February 6, 2018
    Assignee: Gilead Pharmasset LLC
    Inventors: Olga Viktorovna Lapina, Bing Shi, Fang Wang, Scott Alan Wolckenhauer
  • Patent number: 9868745
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: January 16, 2018
    Assignee: Gilead Pharmasset LLC
    Inventors: Elizabeth M. Bacon, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, Evan S. Krygowski, John O. Link, James G. Taylor, Chinh Viet Tran, Teresa Alejandra Trejo Martin, Zheng-Yu Yang, Sheila Zipfel
  • Patent number: 9845299
    Abstract: A novel process for the preparation of a fluorolactone derivative of the formula and of its acylated derivative of formula wherein R1 stands for a hydroxy protecting group is described. The acylated fluor lactones of formula V, particularly the benzoyl derivative with R1=benzyl are important precursors for the synthesis of prodrug compounds which have the potential to be potent inhibitors of the Hepatitis C Virus (HCV) NS5B polymerase.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: December 19, 2017
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Rongmin Chen, Yuanqiang Li, Jianqiang Zhao, Jianbing Zheng, Guoliang Zhu
  • Patent number: 9809600
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: November 7, 2017
    Assignee: Gilead Pharmasset LLC
    Inventors: Elizabeth M. Bacon, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, Evan S. Krygowski, John O. Link, James G. Taylor, Chinh Viet Tran, Teresa Alejandra Trejo Martin, Zheng-Yu Yang, Sheila M. Zipfel
  • Patent number: 9757406
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 12, 2017
    Assignee: Gilead Pharmasset LLC
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • Publication number: 20170253584
    Abstract: The present invention provides (i) processes for preparing a 2?-deoxy-2?-fluoro-2?-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2?-deoxy-2?-fluoro-2?-C-methyl-?-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.
    Type: Application
    Filed: February 6, 2017
    Publication date: September 7, 2017
    Applicant: Gilead Pharmasset LLC
    Inventors: Byoung Kwon Chun, Jinfa Du, Suguna Rachakonda, Peiyuan Wang
  • Patent number: 9718807
    Abstract: The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula I.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: August 1, 2017
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Robert William Scott, Justin Philip Vitale, Kenneth Stanley Matthews, Martin Gerald Teresk, Alexandra Formella, Jared Wayne Evans
  • Patent number: 9682989
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: June 20, 2017
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Elizabeth M. Bacon, Jeromy J. Cottell, John O. Link, Teresa Alejandra Trejo Martin
  • Patent number: 9682987
    Abstract: Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: June 20, 2017
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Erik Mogalian, Robert William Scott, Bing Shi, Fang Wang
  • Patent number: 9676808
    Abstract: Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2?,4?-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: June 13, 2017
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Jinfa Du, Michael Joseph Sofia
  • Patent number: 9670187
    Abstract: The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: June 6, 2017
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Kevin M. Allan, Shinji Fujimori, Lars V. Heumann, Grace May Huynh, Katie Ann Keaton, Christopher M. Levins, Ganapati Reddy Pamulapati, Benjamin James Roberts, Keshab Sarma, Martin Gerald Teresk, Xiang Wang, Scott Alan Wolckenhauer